1. Home
  2. TOVX vs SKY Comparison

TOVX vs SKY Comparison

Compare TOVX & SKY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TOVX
  • SKY
  • Stock Information
  • Founded
  • TOVX 2001
  • SKY 2010
  • Country
  • TOVX United States
  • SKY United States
  • Employees
  • TOVX 22
  • SKY N/A
  • Industry
  • TOVX Biotechnology: Pharmaceutical Preparations
  • SKY Homebuilding
  • Sector
  • TOVX Health Care
  • SKY Consumer Discretionary
  • Exchange
  • TOVX Nasdaq
  • SKY Nasdaq
  • Market Cap
  • TOVX 3.2M
  • SKY N/A
  • IPO Year
  • TOVX 2006
  • SKY N/A
  • Fundamental
  • Price
  • TOVX $1.14
  • SKY $96.03
  • Analyst Decision
  • TOVX Strong Buy
  • SKY Hold
  • Analyst Count
  • TOVX 1
  • SKY 5
  • Target Price
  • TOVX $6.00
  • SKY $85.40
  • AVG Volume (30 Days)
  • TOVX 97.3K
  • SKY 1.3M
  • Earning Date
  • TOVX 11-12-2024
  • SKY 02-03-2025
  • Dividend Yield
  • TOVX N/A
  • SKY N/A
  • EPS Growth
  • TOVX N/A
  • SKY N/A
  • EPS
  • TOVX N/A
  • SKY 2.58
  • Revenue
  • TOVX N/A
  • SKY $2,340,474,000.00
  • Revenue This Year
  • TOVX N/A
  • SKY $20.55
  • Revenue Next Year
  • TOVX N/A
  • SKY $7.01
  • P/E Ratio
  • TOVX N/A
  • SKY $37.16
  • Revenue Growth
  • TOVX N/A
  • SKY 16.86
  • 52 Week Low
  • TOVX $1.14
  • SKY $64.82
  • 52 Week High
  • TOVX $17.00
  • SKY $116.49
  • Technical
  • Relative Strength Index (RSI)
  • TOVX 36.15
  • SKY 38.51
  • Support Level
  • TOVX $1.23
  • SKY $93.06
  • Resistance Level
  • TOVX $1.21
  • SKY $110.09
  • Average True Range (ATR)
  • TOVX 0.07
  • SKY 3.70
  • MACD
  • TOVX 0.01
  • SKY -1.64
  • Stochastic Oscillator
  • TOVX 0.00
  • SKY 12.68

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: